Overview

Merestinib on Bone Metastases in Subjects With Breast Cancer

Status:
Terminated
Trial end date:
2019-06-24
Target enrollment:
Participant gender:
Summary
This is an open label, pharmacodynamics, intrapatient dose escalation phase 1B study.
Phase:
Phase 1
Details
Lead Sponsor:
University of Utah
Collaborator:
Eli Lilly and Company